Aziz Sawaf Will Join Vir Biotechnology as CFO

The biopharmaceutical company will appoint the industry veteran to lead its finance and IT divisions on October 5, 2026.

Updated on Oct. 1, 2026 in People

Aziz Sawaf Will Join Vir Biotechnology as CFO

Live Poll

Do you trust that new executive appointments typically improve a company's long-term performance?

Vir Biotechnology has announced the appointment of Aziz Sawaf as its new Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf will be responsible for overseeing the San Francisco-based company's finance, investor relations, and IT departments.

Why it matters

The leadership change aims to bolster the company's financial operations and strategic execution as it continues to advance its clinical programs. Sawaf brings over two decades of experience to the role, positioning him to manage the firm's capital allocation and operational goals.

Sawaf brings over 20 years of professional experience in the biopharmaceutical industry to his new role. He will manage finance, IT, and investor relations functions for the San Francisco-based firm.

The players

Aziz Sawaf

He is a veteran biopharmaceutical executive who previously held senior financial leadership positions at Theravance Biopharma and Gilead Sciences.

Vir Biotechnology

This San Francisco-based immunology company focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.

Theravance Biopharma

This is a biopharmaceutical company focused on the discovery and development of organ-selective medicines for inflammatory and immunology-related conditions.

The details

Sawaf joins the company from Theravance Biopharma, where he served in various financial and leadership roles since 2014, including CFO and Senior Vice President of Operations Strategy. He holds degrees from the University of Arizona, the University of Southern California, and Johns Hopkins University.

Aziz Sawaf began his career at Theravance Biopharma in 2014.
Sawaf served as CFO of Theravance Biopharma starting in 2023.
He took on the role of Senior Vice President of Operations Strategy in 2025.
He assumes the position of Vir Biotechnology CFO on October 5, 2026.

Market Landscape

The appointment follows a broader trend of talent migration within the San Francisco life sciences corridor, where executives with deep operational expertise frequently transition between regional biotechnology firms. This move positions Vir Biotechnology to leverage Sawaf's background in both financial management and operational strategy to maintain its competitive stance.

For investors and shareholders, the appointment signals a continued emphasis on disciplined capital allocation and programmatic advancement. Clients and partners can expect a continuation of the company's existing investor relations and financial reporting framework under Sawaf's leadership.

The takeaway

Sawaf plans to maintain a focus on disciplined capital allocation to drive patient-centered program development. His extensive background in both finance and operations strategy provides a foundation for him to oversee both the technical and investor-facing sides of the business.